These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12808270)

  • 21. Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in-stent restenosis after drug-eluting or bare-metal stent implantation. The Nordic Intravascular Ultrasound Study (NIVUS).
    Jensen LO; Vikman S; Antonsen L; Kosonen P; Niemelä M; Christiansen EH; Kervinen K; Erglis A; Harnek J; Kumsars I; Thuesen L; Niemelä K
    Cardiovasc Revasc Med; 2017 Dec; 18(8):577-582. PubMed ID: 29066343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial.
    Ko YG; Kim BK; Lee BK; Kang WC; Choi SH; Kim SW; Lee JH; Lee M; Honda Y; Fitzerald PJ; Shim WH;
    Trials; 2011 Jan; 12():10. PubMed ID: 21226953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of plaque debulking before stent implantation on in-stent neointimal proliferation: a serial 3-dimensional intravascular ultrasound study.
    Takeda Y; Tsuchikane E; Kobayashi T; Terai K; Kobayashi Y; Nakagawa T; Sakurai M; Awata N; Kobayashi T
    Am Heart J; 2003 Jul; 146(1):175-82. PubMed ID: 12851628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.
    Katayama T; Ueba H; Tsuboi K; Kubo N; Yasu T; Kuroki M; Saito M; Momomura S; Kawakami M
    Am Heart J; 2007 May; 153(5):762.e1-7. PubMed ID: 17452150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
    Kamishirado H; Inoue T; Mizoguchi K; Uchida T; Nakata T; Sakuma M; Takayanagi K; Morooka S
    Am Heart J; 2002 Aug; 144(2):303-8. PubMed ID: 12177649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT).
    Tsuchikane E; Kobayashi T; Kobayashi T; Takeda Y; Otsuji S; Sakurai M; Awata N
    Am J Cardiol; 2002 Sep; 90(6):573-8. PubMed ID: 12231079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.
    Ujiie Y; Hirosaka A; Mitsugi M; Ohwada T; Igarashi M; Kijima M; Komatsu N; Hisa S; Abe Y; Tsuda T; Yaoita H; Maehara K; Maruyama Y
    Int Heart J; 2006 Mar; 47(2):173-84. PubMed ID: 16607045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of combination therapy with cilostazol and probucol versus monotherapy with cilostazol on coronary plaque, lipid and biomarkers: SECURE study, a double-blind randomized controlled clinical trial.
    Ko YG; Choi SH; Chol Kang W; Kwon Lee B; Wook Kim S; Shim WH
    J Atheroscler Thromb; 2014; 21(8):816-30. PubMed ID: 24705623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular response to sirolimus-eluting stents delivered with a nonaggressive implantation technique: comparison of intravascular ultrasound results from the multicenter, randomized E-SIRIUS, and SIRIUS trials.
    Hoffmann R; Guagliumi G; Musumeci G; Reimers B; Petronio AS; Disco C; Amoroso G; Moses JW; Fitzgerald PJ; Schofer J; Leon MB; Breithardt G
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):499-506. PubMed ID: 16273564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic approaches to restenosis prevention.
    Douglas JS
    Am J Cardiol; 2007 Sep; 100(5A):10K-6K. PubMed ID: 17719348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
    Takagi T; Yamamuro A; Tamita K; Yamabe K; Katayama M; Mizoguchi S; Ibuki M; Tani T; Tanabe K; Nagai K; Shiratori K; Morioka S; Yoshikawa J
    Am Heart J; 2003 Aug; 146(2):E5. PubMed ID: 12891212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization.
    Tanous D; Bräsen JH; Choy K; Wu BJ; Kathir K; Lau A; Celermajer DS; Stocker R
    Atherosclerosis; 2006 Dec; 189(2):342-9. PubMed ID: 16529750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
    Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
    Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES).
    Serruys PW; Sianos G; Abizaid A; Aoki J; den Heijer P; Bonnier H; Smits P; McClean D; Verheye S; Belardi J; Condado J; Pieper M; Gambone L; Bressers M; Symons J; Sousa E; Litvack F
    J Am Coll Cardiol; 2005 Jul; 46(2):253-60. PubMed ID: 16022951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of AGI-1067 and probucol after percutaneous coronary interventions.
    Tardif JC; Grégoire J; Schwartz L; Title L; Laramée L; Reeves F; Lespérance J; Bourassa MG; L'Allier PL; Glass M; Lambert J; Guertin MC;
    Circulation; 2003 Feb; 107(4):552-8. PubMed ID: 12566365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative analysis of intimal hyperplasia after sirolimus-eluting stent and thin-strut bare-metal stent implantation in small coronary arteries].
    Devito FS; Sousa AG; Feres F; Abizaid AA; Staico R; Mattos LA; Tanajura LF; Abizaid AC; Chaves AJ; Sousa JE
    Arq Bras Cardiol; 2006 Apr; 86(4):268-75. PubMed ID: 16680291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation.
    Takebayashi H; Mintz GS; Carlier SG; Kobayashi Y; Fujii K; Yasuda T; Costa RA; Moussa I; Dangas GD; Mehran R; Lansky AJ; Kreps E; Collins MB; Colombo A; Stone GW; Leon MB; Moses JW
    Circulation; 2004 Nov; 110(22):3430-4. PubMed ID: 15557367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting.
    Hong YJ; Jeong MH; Lim SY; Lee SR; Kim KH; Sohn IS; Park HW; Kim JH; Kim W; Ahn Y; Cho JG; Park JC; Kang JC
    Circ J; 2005 Dec; 69(12):1477-83. PubMed ID: 16308495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between neointimal regrowth and mechanism of acute lumen gain during the treatment of in-stent restenosis with or without supplementary intravascular radiation.
    Morino Y; Limpijankit T; Honda Y; Somrantin M; Waksman R; Bonneau HN; Yock PG; Mintz GS; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2003 Feb; 58(2):162-7. PubMed ID: 12552537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.